Table 1.

Selected model input parameters, including transition probabilities, costs, and utilities

Inputs: outcome probabilitiesBase caseSensitivity analysis rangeMonte Carlo distributionReferences
Therapies in the second-line setting     
axi-cel     
Overall outcomes     
EFS rate at 2 y 0.41 0.35-0.52 β 5  
OS rate at 2 y 0.61 0.45-0.78 β 5  
Progression-free survival rate at 2 y 0.46 0.37-0.67 β 5  
Adverse events     
CRS (any grade) 0.92 0.7-1.1 β 5  
CRS (grade ≥3) 0.06 0.03-0.1 β 5  
SOC     
Overall outcomes     
EFS rate at 2 y 0.16 0.10-0.21 β 5  
OS rate at 2 y 0.52 0.38-0.73 β 5  
Progression-free survival rate at 2 y 0.27 0.12-0.42 β 5  
Salvage chemoimmunotherapy     
CR after salvage 0.32 0.2-0.5 β 17  
PR after salvage 0.18 0.05-0.3 β 17  
Stable disease after salvage 0.18 0.05-0.3 β 17  
auto-SCT     
Receipt of transplantation after CR with salvage 0.80 0.70-0.94 β 17  
Receipt of transplantation after PR with salvage 0.54 0.58-0.78 β 17  
OS rate after CR + SCT after 1 y 0.83 0.70-0.97 β 17  
OS rate after PR + SCT after 1 y 0.59 0.45-0.72 β 17  
Adverse events     
Febrile neutropenia (grade ≥3) 0.27 0.1-0.5 β 5  
Anemia requiring blood transfusion (grade ≥3) 0.39 0.1-0.6 β 5  
Leukopenia (grade ≥3) 0.22 0.05-0.9 β 5  
Therapies in the third-line setting     
axi-cel     
CR after CAR-T 0.58 0.49-0.67 β 2  
PR after CAR-T 0.24 0.17-0.33 β 2  
OS rate after 4 y 0.44 0.34-0.54 β 2  
EFS after 2 y 0.38 0.31-0.41 β 2  
Salvage chemoimmunotherapy + auto-SCT (after second-line CAR-T)     
Overall response rate 0.30 0.1 – 0.5 β 1,20  
Receipt of transplantation after CR with salvage 0.30 0.2-0.6 β Expert opinion 
Receipt of transplantation after PR with salvage 0.10 0.05-0.3 β Expert opinion 
Costs     
Inputs: Costs, 2021 US dollars     
Pharmaceutical     
Salvage chemoimmunotherapy 20 762 20 000-100 000 γ 21  
axi-cel 393 104 200 000-700 000 γ 22  
Administration and adverse events     
Salvage chemoimmunotherapy 14 649 14 000-44 000 γ 21,23  
axi-cel 59 124 35 000-70 000 γ 21,23  
auto-SCT 139 194 70 000-190 000 γ 23,24  
Utilities     
Inputs: utilities, QALYs     
RR-DLBCL 0.63 0.3-0.8 β 25  
auto-SCT therapy (2 mo) 0.43 0.2-0.6 β 26  
CAR-T (2 mo) 0.50 0.3-0.7 β 26  
Remission after CAR-T 0.70 0.6-0.9 β 26  
Progression after CAR-T 0.45 0.1-0.6 β 26  
Inputs: outcome probabilitiesBase caseSensitivity analysis rangeMonte Carlo distributionReferences
Therapies in the second-line setting     
axi-cel     
Overall outcomes     
EFS rate at 2 y 0.41 0.35-0.52 β 5  
OS rate at 2 y 0.61 0.45-0.78 β 5  
Progression-free survival rate at 2 y 0.46 0.37-0.67 β 5  
Adverse events     
CRS (any grade) 0.92 0.7-1.1 β 5  
CRS (grade ≥3) 0.06 0.03-0.1 β 5  
SOC     
Overall outcomes     
EFS rate at 2 y 0.16 0.10-0.21 β 5  
OS rate at 2 y 0.52 0.38-0.73 β 5  
Progression-free survival rate at 2 y 0.27 0.12-0.42 β 5  
Salvage chemoimmunotherapy     
CR after salvage 0.32 0.2-0.5 β 17  
PR after salvage 0.18 0.05-0.3 β 17  
Stable disease after salvage 0.18 0.05-0.3 β 17  
auto-SCT     
Receipt of transplantation after CR with salvage 0.80 0.70-0.94 β 17  
Receipt of transplantation after PR with salvage 0.54 0.58-0.78 β 17  
OS rate after CR + SCT after 1 y 0.83 0.70-0.97 β 17  
OS rate after PR + SCT after 1 y 0.59 0.45-0.72 β 17  
Adverse events     
Febrile neutropenia (grade ≥3) 0.27 0.1-0.5 β 5  
Anemia requiring blood transfusion (grade ≥3) 0.39 0.1-0.6 β 5  
Leukopenia (grade ≥3) 0.22 0.05-0.9 β 5  
Therapies in the third-line setting     
axi-cel     
CR after CAR-T 0.58 0.49-0.67 β 2  
PR after CAR-T 0.24 0.17-0.33 β 2  
OS rate after 4 y 0.44 0.34-0.54 β 2  
EFS after 2 y 0.38 0.31-0.41 β 2  
Salvage chemoimmunotherapy + auto-SCT (after second-line CAR-T)     
Overall response rate 0.30 0.1 – 0.5 β 1,20  
Receipt of transplantation after CR with salvage 0.30 0.2-0.6 β Expert opinion 
Receipt of transplantation after PR with salvage 0.10 0.05-0.3 β Expert opinion 
Costs     
Inputs: Costs, 2021 US dollars     
Pharmaceutical     
Salvage chemoimmunotherapy 20 762 20 000-100 000 γ 21  
axi-cel 393 104 200 000-700 000 γ 22  
Administration and adverse events     
Salvage chemoimmunotherapy 14 649 14 000-44 000 γ 21,23  
axi-cel 59 124 35 000-70 000 γ 21,23  
auto-SCT 139 194 70 000-190 000 γ 23,24  
Utilities     
Inputs: utilities, QALYs     
RR-DLBCL 0.63 0.3-0.8 β 25  
auto-SCT therapy (2 mo) 0.43 0.2-0.6 β 26  
CAR-T (2 mo) 0.50 0.3-0.7 β 26  
Remission after CAR-T 0.70 0.6-0.9 β 26  
Progression after CAR-T 0.45 0.1-0.6 β 26  

CR, complete response; PR, partial response.

View Large
This Feature Is Available To Subscribers Only

or Create an Account

Close Modal
Close Modal